Table 3.
Median duration of multi-modality treatment by stage, year of diagnosis and median age
| Median duration of multi-modality therapy in weeks (IQR) | p-value | |
|---|---|---|
| Breast | ||
| Stage | ||
| I | 17.6 (14.0–25.0) | < 0.001 |
| II | 27.6 (20.3–34.0) | |
| III | 30.4 (22.7–36.1) | |
| Year of diagnosis | ||
| 2010–11 | 25.3 (15.7–33.3) | < 0.001 |
| 2012–13 | 24.3 (16.6–32.3) | |
| 2014–15 | 23.3 (18.9–29.3) | |
| 2016 | 28.0 (18.6–36.8) | |
| Age | ||
| < = 55 (the median) | 26.0 (18.4–33.1) | < 0.001 |
| > 55 | 22.1 (15.7–31.3) | |
| Colorectal | ||
| Stage | ||
| I | 14.3 (4.5–25.3) | < 0.001 |
| II | 22.1 (12.4–30.4) | |
| III | 27.9 (16.0–31.9) | |
| Year of diagnosis | ||
| 2010–11 | 16.3 (11.7–30.1) | < 0.001 |
| 2012–13 | 27.6 (14.7–31.6) | |
| 2014–15 | 28.9 (21.9–32.7) | |
| 2016 | 20.3 (13.5–28.1) | |
| Age | ||
| < = 58 (the median) | 26.3 (14.8–31.0) | 0.18 |
| > 58 | 27.6 (14.0–32.0) | |
| NSCLC | ||
| Stage | ||
| I | 4.1 (1.4–14.5) | < 0.001 |
| II | 16.3 (9.0–19.7) | |
| III | 7.3 (6.0–12.4) | |
| Year of diagnosis | ||
| 2010–11 | 7.0 (5.8–15.8) | 0.002 |
| 2012–13 | 10.1 (6.0–17.0) | |
| 2014–15 | 9.3 (6.0–17.4) | |
| 2016 | 6.7 (6.0–14.5) | |
| Age | ||
| < = 60 (the median) | 10.1 (6.0–17.4) | 0.21 |
| > 60 | 7.0 (5.8–14.2) | |
| Prostate | ||
| Stage | < 0.001 | |
| I | 7.9 (6.9–8.1) | |
| II | 7.3 (5.4–7.7) | |
| III | 7.4 (7.1–7.9) | |
| Year of diagnosis | ||
| 2010–11 | 7.3 (5.7–7.7) | 0.29 |
| 2012–13 | 7.3 (5.4–7.7) | |
| 2014–15 | 7.4 (6.0–7.9) | |
| 2016 | 7.4 (7.0–7.9) | |
| Age | ||
| < = 61 (the median) | 7.3 (5.4–7.9) | 0.57 |
| > 61 | 7.4 (5.0–7.7) | |
Abbreviations: IQR interquartile range